News of the WeekPharmacology

The Puzzling Rise and Fall of a Dark-Horse Alzheimer's Drug

See allHide authors and affiliations

Science  12 Mar 2010:
Vol. 327, Issue 5971, pp. 1309
DOI: 10.1126/science.327.5971.1309

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The announcement last week that a closely watched phase III clinical trial for Alzheimer's disease had failed to show a significant effect deals yet another demoralizing blow to patients, families, and caregivers. It may also mark the beginning of the end to one of the most unusual stories in Alzheimer's drug development. The trial involved a drug called Dimebon, which catapulted into the limelight with a spectacularly successful trial published in 2008.